Stemline Therapeutics, Inc.
(NASDAQ : STML)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
AMGNAmgen Inc.
2.54%200.561.2%$532.16m
GILDGilead Sciences, Inc.
3.71%75.480.9%$476.83m
BIIBBiogen Inc.
1.76%334.191.3%$391.43m
CELGCelgene Corporation
2.13%83.571.2%$346.39m
ILMNIllumina, Inc.
2.19%320.263.5%$304.16m
REGNRegeneron Pharmaceuticals, Inc.
4.77%395.542.6%$239.37m
ALXNAlexion Pharmaceuticals, Inc.
4.82%127.352.0%$225.45m
VRTXVertex Pharmaceuticals Incorporated
3.41%183.701.9%$217.65m
SRPTSarepta Therapeutics, Inc.
5.16%138.1116.4%$179.94m
AAgilent Technologies, Inc.
2.21%67.081.5%$160.96m
BMRNBioMarin Pharmaceutical Inc.
4.29%103.724.4%$141.18m
LGNDLigand Pharmaceuticals Incorporated
5.89%211.8623.3%$122.16m
VKTXViking Therapeutics, Inc.
8.80%15.450.9%$121.89m
NKTRNektar Therapeutics
3.38%50.745.6%$112.74m
EXASExact Sciences Corporation
1.32%66.6425.3%$104.38m

Company Profile

Stemline Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the discovery, acquisition, development, and commercialization of novel therapeutics for oncology indications of unmet medical need. Its clinical stage product candidates include SL-401, SL-801, and SL-701. The SL-401, is a targeted therapy directed to the interleukin-3 receptor (CD123) present on a malignancies. The SL-801, is a novel oral small molecule reversible inhibitor of XPO1, that has demonstrated in vivo and in vitro preclinical activity in a solid and hematologic malignancies. The SL-701, is an immunotherapy designed to activate the immune system to attack tumors. The company was founded by Ivan Bergstein on August 8, 2003 and is headquartered in New York, NY.